Shortening the Haemophilia Activities List (HAL) from 42 items to 18 items
Kuijlaars, Isolde A.R.; van der Net, Janjaap; Buckner, Tyler W.; Kempton, Christine L.; Schutgens, Roger E.G.; Fischer, Kathelijn
(2021) Haemophilia, volume 27, issue 6, pp. 1062 - 1070
(Article)
Abstract
Introduction: The Haemophilia Activities List (HAL) was developed to measure activities and participation in persons with haemophilia (PWH). Shortening the questionnaire may facilitate use of the HAL. Aim: The aim of this study was to determine which items of the HAL are redundant, to construct a shorter version of the
... read more
HAL, and to determine the construct validity of the HALshort. Methods: A secondary analysis was performed on pooled data of two published studies using the HAL (seven domains, 42 items, optimum score: 100) in adults with haemophilia A/B. Data were divided into a derivation (62%) and a validation set (38%). Redundant items were identified by evaluation of: floor and ceiling effects, proportions of missing and ‘not applicable’ responses, inter-item correlations, component loadings in an exploratory factor analysis, internal consistency, and item-total correlations. Correlations with the SF-36 and EQ-5D-5L were used to determine construct validity of the HALshort. Results: Data on 680 PWH were evaluated. In the derivation dataset (n = 420), median age was 30 years (range 18–80), 43% had severe haemophilia and 61% received prophylaxis. Median (IQR) HAL sum score was 65.0 (55.7–88.8). The stepwise procedure resulted in a HALshort of 18 items with a median sum score of 63.3 (54.4–86.7). Construct validity was similar for the HAL and HALshort in the validation dataset (n = 260). Conclusion: This clinimetric study resulted in a >50% shortening of the HAL. The 18-item HALshort reduces patient burden and is expected to capture the information on activities and participation. The HALshort needs further validation.
show less
Download/Full Text
Keywords: activities, haemophilia, participation, patient-reported outcome, Hematology, Genetics(clinical), Journal Article
ISSN: 1351-8216
Publisher: Wiley-Blackwell
Note: Funding Information: The Van Creveldkliniek has received speaker's fees from Bayer, Baxter/Shire, SOBI/Biogen, CSL Behring and NovoNordisk; has performed consultancy for Bayer, Biogen, CSL‐Behring, Freeline, NovoNordisk, Roche and SOBI; and has received research support from Bayer, Baxter/Shire, Novo Nordisk, Pfizer and Biogen for work done by K. Fischer. K. Fischer is member of the group that developed the HAL. T.W. Buckner received honoraria for advisory board participation from Novo Nordisk, Takeda, CSL Behring, Bayer, Tremeau Pharmaceuticals, Spark, Pfizer; served as consultant to uniQure, BioMarin, and Tremeau Pharmaceuticals. T.W. Buckner is on the board of directors for the American Thrombosis and Hemostasis Network. C.L. Kempton received honoraria for Advisory Board Participation from Sanofi, Takeda, and Spark. I.A.R. Kuijlaars, J. van der Net and R.E.G. Schutgens do not have any conflict of interest regarding this manuscript other than membership of the group that developed the HAL. The other authors have no competing interests. Publisher Copyright: © 2021 The Authors. Haemophilia published by John Wiley & Sons Ltd.
(Peer reviewed)